MARI — Marinomed Biotech AG Balance Sheet
0.000.00%
Last trade - 00:00- €19.69m
- €33.17m
- €7.69m
Annual balance sheet for Marinomed Biotech AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 5.8 | 8.18 | 2.59 | 1.71 | 0.952 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.81 | 3.12 | 2.39 | 0.907 | 0.335 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 12.9 | 14.3 | 7.14 | 3.29 | 1.43 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.43 | 6.2 | 5.94 | 4.79 | 4.51 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 21.3 | 22.3 | 14.6 | 8.18 | 5.95 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.01 | 5.96 | 9.65 | 5 | 3.77 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 21.1 | 26.4 | 24.7 | 34.3 | 13 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.191 | -4.16 | -10.1 | -26.2 | -7.05 |
| Total Liabilities & Shareholders' Equity | 21.3 | 22.3 | 14.6 | 8.18 | 5.95 |
| Total Common Shares Outstanding |